PrintFriendly
Industry News
|
Thursday, August 17, 2017  Specifically, Pfizer will expand an 11,000-square-foot plant in Sanford, North Carolina that it acquired last year when it bought Bamboo Therapeutics, a biotech company that specializes in gene therapies for certain rare diseases. |
|
Monday, August 14, 2017  Spark Therapeutics, Inc. recently released preliminary data from a phase 1/2 dose-escalation clinical trial for SPK-8011, the company’s investigational gene therapy candidate for hemophilia A. |
|
Tuesday, August 8, 2017  New online learning activity entitled, “An Overview of the Background, Inheritance and Physiology of von Willebrand Disease,” is now available. |
|
Friday, August 4, 2017  UniQure N.V. has announced that is has “scaled up” the manufacturing process at its large facility in Lexington, MA. |
|
Tuesday, August 1, 2017  BioMarin Pharmaceutical, Inc. recently provided updated interim results from a phase 1/2 clinical study of BMN 270, the company’s investigational hemophilia A gene therapy. |
|
Thursday, July 13, 2017  The program will allow bleeding disorders camp staff learn from one another and share best practices. |
|
Tuesday, July 11, 2017  Alnylam reports the latest Phase 2 study showed that the safety and tolerability associated with fitusiran “remains encouraging.” |
|
Monday, July 10, 2017  If effective, the therapy prompts the sustained production of FVIII and enhanced protection from bleeds. |
|
Wednesday, July 5, 2017  Results showed a statistically significant and clinically meaningful reduction in bleed rate, reports states. |
|
Friday, June 2, 2017  FDA approves the Biologics License Application (BLA) for REBINYN® |